- Home
- LFST vs EVO Comparison
LFST vs EVO Comparison
Compare LFST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- EVO
- Stock Information
- Founded
- LFST 2015
- EVO 1993
- Country
- LFST United States
- EVO Germany
- Employees
- LFST N/A
- EVO N/A
- Industry
- LFST Medical/Nursing Services
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- EVO Health Care
- Exchange
- LFST Nasdaq
- EVO Nasdaq
- Market Cap
- LFST 2.1B
- EVO 1.2B
- IPO Year
- LFST 2021
- EVO 2021
- Fundamental
- Price
- LFST $5.15
- EVO $3.64
- Analyst Decision
- LFST Strong Buy
- EVO Buy
- Analyst Count
- LFST 5
- EVO 2
- Target Price
- LFST $8.60
- EVO $5.40
- AVG Volume (30 Days)
- LFST 2.1M
- EVO 41.3K
- Earning Date
- LFST 11-06-2025
- EVO 11-05-2025
- Dividend Yield
- LFST N/A
- EVO N/A
- EPS Growth
- LFST N/A
- EVO N/A
- EPS
- LFST N/A
- EVO N/A
- Revenue
- LFST $1,316,483,000.00
- EVO $912,894,891.00
- Revenue This Year
- LFST $15.27
- EVO $0.39
- Revenue Next Year
- LFST $14.29
- EVO $9.53
- P/E Ratio
- LFST N/A
- EVO N/A
- Revenue Growth
- LFST 13.86
- EVO N/A
- 52 Week Low
- LFST $3.74
- EVO $2.84
- 52 Week High
- LFST $8.61
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- LFST 48.15
- EVO 52.36
- Support Level
- LFST $5.11
- EVO $3.43
- Resistance Level
- LFST $5.31
- EVO $3.55
- Average True Range (ATR)
- LFST 0.20
- EVO 0.08
- MACD
- LFST -0.07
- EVO 0.04
- Stochastic Oscillator
- LFST 7.14
- EVO 80.00
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.